9.3 C
New York
Monday, March 4, 2024

Sutro: Luveltamab Data At ESMO Signifies Continued ADC Advancement

Sutro: Luveltamab Data At ESMO Signifies Continued ADC Advancement


Voronchuk Daria/iStock via Getty Images

Sutro Biopharma (NASDAQ:STRO) was able to report positive results from its Phase 1 dose expansion study using luveltamab tazevibulin (STRO-002) for the treatment of patients with recurrent folate receptor alpha endometrial cancer (EC). (FRa). In



Source link

Latest stories